These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24842649)

  • 21. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
    Fava M; Mallinckrodt CH; Detke MJ; Watkin JG; Wohlreich MM
    J Clin Psychiatry; 2004 Apr; 65(4):521-30. PubMed ID: 15119915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
    Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
    J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is duloxetine effective treatment for depression with atypical features?
    Stewart JW; Deliyannides DA; McGrath PJ
    Int Clin Psychopharmacol; 2008 Nov; 23(6):333-6. PubMed ID: 18854721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants.
    Mancini M; Wade AG; Perugi G; Lenox-Smith A; Schacht A
    J Psychiatr Res; 2014 Apr; 51():21-9. PubMed ID: 24462042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
    Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
    Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
    Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression.
    Rosso G; Rigardetto S; Bogetto F; Maina G
    J Affect Disord; 2012 Jan; 136(1-2):172-176. PubMed ID: 21862138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials.
    Harada E; Kato M; Fujikoshi S; Wohlreich MM; Berggren L; Tokuoka H
    Int J Clin Pract; 2015 Oct; 69(10):1139-48. PubMed ID: 25980552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
    Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
    Curr Med Res Opin; 2012 Jan; 28(1):41-8. PubMed ID: 22126422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
    Davidson JR; Wittchen HU; Llorca PM; Erickson J; Detke M; Ball SG; Russell JM
    Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.
    Mease PJ; Russell IJ; Kajdasz DK; Wiltse CG; Detke MJ; Wohlreich MM; Walker DJ; Chappell AS
    Semin Arthritis Rheum; 2010 Jun; 39(6):454-64. PubMed ID: 19152958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
    Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.